EXHIBIT A

of Supplemental Information Disclosure Statement filed July 15, 2008

Applicants: David Baltimore, et al.

Serial No.: 10/037,341 Filed: January 4, 2002 Group Art Unit: 1636 Examiner: D. Guzo

Form P	ΓΟ-1	449 Substitute U.S. Department of Commerce Application Number	10/037.341				
		Patent and Trademark Office Filing Date	January 4, 2002				
			David Baltimore				
INFORM	ИАТ	TON DISCLOSURE STATEMENTS	et al.				
		sheets if necessary) Art Unit Examiner Name Attorney Docket No.	1636				
		Examiner Name	D. Guzo				
		Attorney Docket No.	75723-ZA/JPW/GJ				
	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹						
	+	December 16, 2005 Condensed Deposition of Lauri-Glimcher in Civil Case 02 CV 11280 RWZ including Exhibits 1-13 attached with this Third Supplement Information Disclosure Statement, namely: Curri-Of Laurie H. Glimcher [DDX 385 12/16/05]; Glick Review Article Drugs, (2004), 837-859 [DDX388 1 Opal 105]; Opal and Huber, Critical Care, (2002 [DDX389 12/16/05]; Joyce et al., The Journal of Chemistry, (2001), 276:11199-11203 [DDX390 12/1 and Grinnell, Crit. Care Med, (2002), 30:S288-S12/16/05]; Brun-Buisson et al., JAMA, (1995), 2 [DDX392 12/16/05]; Joyce et al., The Journal of Chemistry, (2001), 276:11199-11203 [DDX393 12/1 Brueckmann et al., Inflamm. Res. (2004), 528-53 12/16/05]; Leeuwen et al., Crit Care Med (2001) 1077 [DDX395 12/16/05]; Derhaschnig et al., Blo 102:2093-2098 [DDX396 12/16/05]; Kalil et al., (2004), 21:222-229 [DDX397 12/16/05]; Nick et a (2004), 104:3878-3885 [DDX398 12/16/05]; Dhaina Care Med. (2004) 32Supp:S194-S201 [DDX399 12/16	g deposition ntal culum Vitae and Opal, 2/16/05 &), 6:125-136 Biological 6/05]; Joyce 293 [DDX391 74:968-974 Biological 6/05]; 3 [DDX394 , 29:1074- od. (2003), Chock, l., Blood, ut, Crit				
	2	Rule 26(A)(2) Rebuttal Report of Thomas R. Kade dated October 21, 2005 in Civil Case 02 CV 1128 including Exhibits 1-71 attached with this Four Supplemental Information Disclosure Statement, Patent No. 5,500,365, issued March 19, 1996, Fial.; U.S. Patent No. 5,625,136, issued April 29 Koziel et al.; File History of U.S. Serial No. filed April 6, 1995; U.S. Patent No. 5,804,374, September 8, 1998, Baltimore et al.; U.S. Patent 5,939,421, issued August 17, 1999, Palanki et allistory of 06/946,365, filed December 24, 1986; History of U.S. Serial No. 06/817,441, filed Jan 1986; U.S. Patent No. 6,060,310, issued May 9, Chung; File History of U.S. Serial No. 07/791,89 November 13, 1991; U.S. Patent No. 6,410,516, is 25, 2002, Baltimore et al.; U.S. Patent No. 6,88	O RWZ th namely: U.S. schhoff et , 1997, 08/418,266, issued t No. l.; File File nuary 9, 2000, Cho- 98, issued ssued June				

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Applicants: David Baltimore, et al.

Serial No.: 10/037,341 Filed: January 4, 2002

Exhibit A

Form PTO-1449 Substitute

U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Application Number	10/037,341
Filing Date	January 4, 2002
First Named Inventor	David Baltimore
First Named Inventor	et al.
Art Unit	1636
	D. Guzo
Attorney Docket No.	75723-ZA/JPW/GJG

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2 con t.	issued January 11, 2005, Gerlitz et al.; File History of U.S. Serial No. 07/155,207, filed February 12, 1988; File History of U.S. Serial No. 07/162,680, filed March 1, 1988; File History of U.S. Serial No. 07/280,173, filed December 5, 1988; File History of U.S. Serial No. 07/318,901, filed March 3, 1989; File History of U.S. Serial No. 07/318,901, filed March 3, 1989; File History of U.S. Serial No. 07/341,436, filed April 21, 1989; Arruda et al., Blood (2005) 105:3458-3464; Kline et al., Int. J. Immunopharmac. (1984) 6:467-473; Ballard et al., Cell (1990) 63:803-814; Bass et al., Proteins: Structure, Function & Genetics (1990) 8:309-314; Berns et al., Breast Cancer Research & Treatment (1984) 4:195-204; Boda et al., Folia Biologica (1987) 33:93-97; Bressler et al., Journal of Virology (1993) 67:288-293; Brown et al., Methods in Enzymology (1993) 67:288-293; Brown et al., Science (1995) 267:1485-1488; Cai et al., The Journal of Biological Chemistry (1997) 272:96-101; Cunningham and Wells, Science (1998) 244:1081-1085; Davis et al., Science (1991) 253:1268-1271; Du et al., Molecular Brain Research (2005) 136:177-188; Esslinger et al., The Journal of Immunology (1997) 158:5075-5078; Curriculum Vitae of Thomas Robert Kadesch dated 4/26/05; Fenteany et al., Science (1995) 268:726-731; Fiedler et al., Am. J. Respir. Cell Mol. Biol. (1998) 19:259-268; Fujihara et al., The Journal of Immnology (2000) 165:1004-1012; Gallop et al., J. Of Medicinal Chemistry (1994) 37:1233-1251; Gehrt et al., The Journal of Antibiotics (1998) 334:721-724; Haskill et al., Cell (1991) 65:1281-1289; Horuk R., Journal of Immunological Methods (1989) 119:255-258; Hoyos et al., Science (1989) 244:457-460; Kawamura et al. Gene Therapy (2001) 905-912; Khaled et al., Clinical Immunology (1998) 86:170-179; Krappmann et al., The EMBO Journal (1996) 15:6716-6726; Kumar et al., Oncogene (1998) 17:913-918; Lenardo and Baltimore, Cell (1989) 58:227-229; Lloyd et al., Nature (1991) 352:635-638; Logeat et al., The EMBO Journal (1991) 10:1827-1832; LyB	

EXAMINER SIGNATURE

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 Substitute

U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Application Number	10/037,341
Filing Date	January 4, 2002
First Named Incomes	David Baltimore
First Named Inventor	et al.
Filing Date First Named Invento Art Unit	1636
Examiner Name	D. Guzo
Filing Date First Named Inventor Art Unit Examiner Name	75723-ZA/JPW/GJG

	NON P	ATENT	LITERATURE	DOCUMENTS
--	-------	-------	------------	-----------

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2 Con t.	McKinney et al., The Journal of Biological Chemistry (1997) 272:22377-22380; McKnight and Kingsbury, Science (1982) 217:316-324; Meng et al., Proc. Natl. Acad. Sci. USA, (1999) 96:10403-10408; Morishita et al., Nature Medicine (1997) 3:894-899; Myers et al., Science (1986) 232:613-618; Nabel et al., Proc. Natl. Acad. Sci. USA, (1996) 93:15388-15393; Nicolau et al., Cell Fusion (1984) pp.254-267; Palombella et al., Proc. Natl. Acad. Sci. USA, (1998) 95:16741-15676; Ray et al., The Journal of Biological Chemistry (1995) 270:10680-10685; Reisine et al., Proc. Natl. Acad. Sci. USA, (1985) 82:8261-8265; Roberts K., Week in Review Desk (1985); Roozemond et al., Immunobiol. (1987) 176:35-46; Sawa et al., Circulation (1997) 96[suppl II]:II-280-II-285; Schindler et al., The Journal of Immunology (1990) 144:2216-2222; Scott and Smith, Science (1990) 249:386-390; Shakhov et al., J. Exp. Med. (1990) 171:35-47; Holden C., Science (1985) 230:302; Tomita et al., J. Hypertens (1998) 16:993-1000; Trepicchio and Krontiris, Nucleic Acids Research (1993) 21:977-985; Tung et al., Proc. Natl. Acad. Sci. USA, (1988) 85:2479-2483; PCT International Application No. WO 90/02809, International Publication Date March 22, 1990; PCT International Application Date March 22, 1990; PCT International Application Date December 13, 1990;	
	3	October 21, 2005 Rule 26(A)(2) Rebuttal Report Of Thomas R. Kadesch, Ph.D. in Civil Case 02 CV 11280 RWZ;	
	4	February 12, 2001 Response and Amendment in U.S. Serial No. 08/464,364, ADL 0000843-0000853, Document 198, filed 02/03/2006, in Civil Case 02 CV 11280 RWZ;	
	5	Davis et al., Science (1991) 253:1268-1271, Document 198, 02/03/2006, in Civil Case 02 CV 11280 RWZ;	
	6	Haskill, et al., Cell (1991) 65:1281-12889, Document 198, filed 02/03/2006, in Civil Case 02 CV 11280 RWZ;	

EXAMINER SIGNATURE

DATE CONSIDERED

Form P	Γ O -1	449 Substitute U.S. Department of Commerce	Application Number	10/037,341	
		Patent and Trademark Office	Filing Date	January 4, 20	002
			First Named Inventor	David Baltimo	ore
INFOR	MAT	ION DISCLOSURE STATEMENT		et al.	
(Use sev	eral :	sheets if necessary)	Art Unit	1636	
`		•	Examiner Name	D. Guzo	
			Attorney Docket No.	75723-ZA/JPW/	/GJC
		NON PATENT LITERATURE DOC	CUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of th (book, magazine, journal, serial, symposium, catalog, etc.) date, p and/or country where pub	age(s), volume-issue nu		T ²
7 March 3, 2004 Memorandum Of Decision And Order on claim construction;					
	8	November 11, 2005 Reply Expert Repo Prescott, paragraphs 16-18;	rt of Dr. St	ephen	
		November 11, 2005 Reply Expert Repo Ravetch, paragraphs 6-9;	rt of Dr. Je	ffrey	
	10	November 11, 2005 Reply Expert Repo Glimcher, page 11 and 12;	rt Of Dr. La	urie H.	
		November 11, 2005 Rule 26(b)(2) Rep Livingston, M.D., pages 17-18;	ly Report of	David M.	
		November 22, 2005 Condensed Deposit in Civil Case 02 CV 11280 RWZ, page 242, line 25 and page 262, line 9 -	226, line 2	4 - page	
		November 30, 2005 Condensed Deposit Ravetch in Civil Case 02 CV 11281 R page 58, line 25;			
		Trial Transcript - April 26, 2006 J Session in Civil Case 02 CV 11281 R and page 124, line 16;			
	15	Curriculum Vitae of Dr. Inder Verma	;		
	16	October 10, 2007 The Amgen Entities Whitehead's First Set of Interrogat No. 06-259 (MPT);			
	17	October 10, 2007 Wyeth's Responses of Interrogatories (Nos. 1-15) in C (MPT);			

EXAMINER SIGNATURE

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Earn DI	· 1	440 Carbaritanta	U.C. Danautusant of Ca		Application Number	10/037 3/1		
Form F1	U -1	449 Substitute	U.S. Department of Co		Application Number Filing Date	January 4, 20	002	
			Patent and Trademark	k Office	Filing Date	David Baltimo		
INITODA	4 A TC	ION DISCLOSI			First Named Inventor	et al.) I C	
			RE STATEMENT		Art Unit	1636		
(Use seve	erai s	sheets if necessar	y)		Examiner Name	D. Guzo		
					Attorney Docket No.	75723-ZA/JPW,	/GJO	
					present a series of the series	, , , , , , , , , , , , , , , , , , , ,		
	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1		author (in CAPITAL LETTER nal, serial, symposium, catalog, and/or countr	, etc.) date, pa	ige(s), volume-issue nu		T ²	
	18	Production o	2007 Wyeth's Second of Documents And Tourney, and Whitehead	Things	(Nos. 22-101) To Ariad,		
			2007 The Amgen Er Interrogatories					
			2007 The Amgen En Interrogatories					
	21	Fourth Set o	2007 The Amgen Enf Requests For Pr 6-259 (MPT);	ntities	Responses on of Docume	to Ariad's nts in Civil		
	22	Responses An	2007 Wyeth's Found Objections To Aries (Nos. 1-25)	Ariad's	First Set o	f		
	23	And Objection	2007 Ariad's And ns To Wyeth's Fin No. 06-259 (MPT)	rst Set				
	24	October 31, And Objection Production of 259 (MPT);	2007 Ariad's And ons To Wyeth's Fire of Documents And	The In rst Set Things	stitutions' of Requests in Civil Act	Responses For ion No. 06-		
	25	Ariad's Sixt	2007 Defendant And h Set of Requests Civil Action No.	s For P	roduction To			
	26	Admission (N	2007 Wyeth's Firstos. 1-160) To Ars Civil Action No	iad, Ha	rvard, MIT,	for and		
EXAMINER SIGNATUR			DATE CON	SIDERED				

10/037,341 Form PTO-1449 Substitute **U.S. Department of Commerce** Application Number Filing Date January 4, 2002 **Patent and Trademark Office** David Baltimore First Named Inventor et al. INFORMATION DISCLOSURE STATEMENT Art Unit 1636 (Use several sheets if necessary) D. Guzo **Examiner Name** Attorney Docket No. 75723-ZA/JPW/GJG NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials No.1 (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. November 7, 2007 The Amgen Entities' Responses To Ariad's 27 Fifth Set of Requests For Production of Documents in Civil Action No. 06-259 (MPT); November 7, 2007 Wyeth's Third Set of Requests For Production of Documents And Things (Nos. 101-109) To Ariad, Harvard, MIT, and Whitehead in Civil Action No. 06-259 (MPT); November 8, 2007 Wyeth's Responses To Ariad's Third Set of 29 Requests For Production of Documents (Nos. 108-121) in Civil Action No. 06-259 (MPT); November 12, 2007 The Amgen Entities' Responses To Ariad's 30 Third Set of Interrogatories in Civil Action No. 06-259 (MPT); November 12, 2007 Wyeth's Responses And Objections To Ariad 31 And The Institutions' Second Set of Interrogatories (Nos. 26-29) in Civil Action No. 06-259 (MPT); November 13, 2007 Defendant And counterclaim Plaintiff 32 Ariad's Fourth Set of Requests For Production of Documents And Things to Wyeth in Civil Action No. 06-259 (MPT); November 15, 2007 Ariad's And The Institutions' Responses 33 And Objections To Wyeth's Second Set of Interrogatories in

EXAMINER SIGNATURE DATE CONSIDERED

Civil Case No. 06-259 (MPT);

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

35 For Production of Documents And things Directed To Ariad And The Institutions in Civil Action No. 06-259 (MPT);

November 15, 2007 The Amgen Entities' Third Set of Requests

November 15, 2007 The Amgen Entities' Second Set of

34 Requests For Admission Directed To Ariad And the Institutions in Civil Action No. 06-259 (MPT);

Form P1	O-1	449 Substitute U.S. Department of Commerce	Application Number 10/037, 341			
		Patent and Trademark Office	Filing Date January 4, 20	002		
			First Named Inventor David Baltimo	re		
INFORM	ИАТ	ION DISCLOSURE STATEMENT	et al.			
(Use sev	eral :	sheets if necessary)	Art Unit 1636			
		•	Examiner Name D. Guzo			
			Attorney Docket No. 75723-ZA/JPW/	'GJC		
		NON PATENT LITERATURE DOC	HMENTS			
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the		T ²		
Initials No. (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city						
and/or country where published.						
		November 15, 2007 Ariad's And the I	nstitutions' Responses			
Ì	36	And Objections To Wyeth's Second Set	t of Requests For			
		Production for Documents And Things	in Civil Action No. 06-			
		259 (MPT);	·			
		Deposition Transcript of Dr. Thomas	R. Kadesch dated June			
		21, 2007, Amgen, Inc. v. F. Hoffmani	n-La Roche Ltd., a Swiss			
	37	Company, Roche Diagnostics GmbH, a (German Company, and			
	Hoffmann-La Roche, Inc., A New Jersey Corporation, U.S. District Court, District of Massachusetts, in Civil Action No. 05-12237 WGY;					
	October 11, 2007 Wyeth's Second Set of Interrogatories To					
		Ariad, The President And Fellows of	Harvard College, The			
	38	Massachusetts Institute of Technolog	gy, And The Whitehead			
		Institute For Biomedical Research in	n Civil Action No. 06-			
		259 (MPT);				
		October 19, 2007 Counterclaim Plain	tiffs Ariad's And The			
	39	Institutions' Second Set of Interro	gatories To Wyeth in			
		Civil Action No. 06-259 (MPT);				
		October 19, 2007 Counterclaim Plain	tiffe Deiedle Ded El			
		Institutions' Third Set of Interroga				
		Entities in Civil Action No. 06-259	(MPT);			
		October 22, 2007 Wyeth's Third Set	of Interrogatories To			
	/ 1	Ariad, The President And Fellows of	Harvard College, The			
	41	Massachusetts Institute of Technolog Institute For Biomedical Research in	gy, And The Whitehead			
		259 (MPT);	TOTAL ACCION NO. U6-			
		November 15, 2007 Amgen Entities' Th	nird Set of			
	42	Interrogatories Directed To Ariad Ar	nd the Institutions in			
		Civil Action No. 06-259 (MPT);				
		January 18, 2008 Expert Report of Ra	andolph Wall Ph D in			
	43	the litigation captioned Amgen, Inc	et al. v. Ariad			
		Pharmaceuticals, Inc., et al., U.S.	District Court for the			
		District of Delaware, CA No. 06-259-	-MPT			
EXAMINER						
SIGNATURI		DATE CONSIDERED		!		

Form P	ΓO-1	449 Substitute	U.S. Department of Commerce	Application Number	10/037,341	
		· · · › Substitute	Patent and Trademark Office	Filing Date	January 4, 20	002
I NEOD!	. # A 710	TON DIGGE OC		First Named Invento	David Baltime	
			JRE STATEMENT	Art Unit	1636	
(Use sev	erai	sheets if necessar	TY)	Examiner Name	D. Guzo	
				Attorney Docket No		/GJC
			NON PATENT LITERATURE DOC			
Examiner Initials	Cite No. ¹		e author (in CAPITAL LETTERS), title of ti rnal, serial, symposium, catalog, etc.) date, p and/or country where pu	he article (when appro page(s), volume-issue n		T ²
	44	Whitehead, I P.30(b)(6), captioned A Inc., et al	ntities' 5 th Notice of De Harvard and MIT Pursuant dated January 25, 2008, Ingen, Inc. et al. v. Ari I., U.S. District Court for No. 06-259-MPT;	to Fed. R.G in the lit	Civ. igation <i>uticals,</i>	
	45	on Amgen's I ARIAD's Cou <i>Inc. et al</i> .	2008 Memorandum Order of Motion to Amend and Supporterclaims in the litigation of the District of	plement Their ation caption ls, Inc., et	r Reply to ned <i>Amgen,</i> al., U.S.	
	46	Ph.D. in the Ariad Pharm	2008 Expert Report of 3 a litigation captioned A aceuticals, Inc., et al.	Amgen, Inc.	et al. v. rict Court	
	47	the litigat Pharmaceuti	2008 Expert Report of Fion captioned Amgen, Inc. als, U.S. Delaware, CA No. 06-259	c. et al. v. District C	Ariad	
	48	Kadesch, Ph Pharmaceuti	2005 Rule 26(A)(2) Rebu.D. in the litigation cacals, Inc. et al. v. Electrication of Z;	aptioned Aria i Lilly and	ad Co., U.S.	
	49	Kadesch in	07 Deposition Transcript the litigation captioned Roche Ltd., et al., U.S	d Amgen, Inc	. v. F.	

EXAMINER SIGNATURE

DATE CONSIDERED

Hoffmann-La Roche Ltd., et al., U.S. District Court for the District of Massachusetts, CA No. 0512237 WGY;

Form PT	'O-1	449 Substitute	U.S. Department of Commerc	e Application Number	10/037,341		
			Patent and Trademark Office		January 4, 20	002	
					David Baltimo		
INFORM	1AT	ION DISCLOSU	RE STATEMENT	First Named Inventor	et al.		
		sheets if necessar		Art Unit	1636		
(,	Examiner Name	D. Guzo		
				Attorney Docket No.	75723-ZA/JPW,	/GJC	
	NON PATENT LITERATURE DOCUMENTS						
Examiner Cite Initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the initials (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher and/or country where published.						T ²	
	50	Patricia Gra Action No. 0 08/464,364 (Dep. Exh. 19 Ariad Plaint Exhibits 1-1 Information of 07/162,68 November 14, {Granahan Ex U.S. Serial Federal Regu corresponden March 22, 19 {Granahan Ex Redacted fro Communicatio Designated O sentence inc 11) EP 0 407	2007 Transcript of Vicenahan, Sc.D., pgs. 1-26-259 (MPT), including Pat. No. 6,410,516) [Fat. No. 196]; 3 iffs Dep. Exh. 196]; 4 iffs Dep. Exh. 198]; 5 iffs Dep. Exh. 200]; 6 iffs Dep. Exh. 200]; 7 iffs Dep. Exh. 201]; 8 iffs Dep. Exh. 201]; 8 iffs Dep. Exh. 202] ar 7 which are attached which Disclosure Statement, 0 [inc. Tabs 1-29] [Gat. 1988 correspondence for 1988 correspondence for 1988 correspondence for 1990 correspondence from No. 07/318,901 [Granahalations [Granahan Exh. Notice Information of the International fices issued under Post 1990 (No. 1990) [Information of the International	35 & A.1-A.23 i) file hist mgen v. Ariad No. 6,150,09) 08/418,266 07/341,436 [) 06/946,365 i) 07/280,173) 07/280,173) 07/791,898 d, ii) deposith this Supp namely: 1) file and Exh. 1 from Patricia for patent ap an Exh. 3); 4 4); 5) Augus an Exh. 3); 4 4); 5) Augus an Exh. 3); 4 Application T Rule 47.1(cn Exh. 9); 10 11); 12) Red	, in Civil ory of: 1) Plaintiffs 0) [Amgen v. tion lemental le history }; 2) Granahan plication) Code of t 10, 1990 Exh. 5); 6) nahan g Procedure . 8}; 9) icant of to the) first) Redacted; acted; 13)		
		Lisa Marie T No. 06-259 (are attached Statement, n Kiyoshi Asam 1996 corresp 7-07}; 3) Ma	2007 Transcript of Vice reannie, pgs. 1-130 & MPT), including deposit with this Supplemental amely: 1) January 18, aura {Treannie Exh. 1, condence from Lisa Warr 17, 1997 correspondent 17, 1997;	A.1-A.13, in tion Exhibits 1 Information 1996 correspo 11-7-07}; 2) en {Treannie	Civil Action 1-6 which Disclosure ndence from February 2, Exh. 2, 11-		
EXAMINER SIGNATURI			DATE CONSIDERED				

Form P1	O-1	449 Substitute U.S. Department of Commerce	Application Number	10/037,341	
		Patent and Trademark Office	Filing Date	January 4, 20	002
				David Baltimo	
INFORM	ЛАТ	ION DISCLOSURE STATEMENT	First Named Inventor	et al.	
		sheets if necessary)	Art Unit	1636	
(030 30)		sircets if freeessary)	Examiner Name	D. Guzo	
			Attorney Docket No.	75723-ZA/JPW	/GJC
				·	
		NON PATENT LITERATURE DOC	CUMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of ti (book, magazine, journal, serial, symposium, catalog, etc.) date, p and/or country where pul	age(s), volume-issue nu	riate), title of the item mber(s), publisher, city	T ²
51 4) correspondence from Patricia Granahan {Treannie Exh. 4, 11-7-07}; 5) July 8, 1997 correspondence from Lisa M. Con Warren {Treannie Exh. 5, 11-7-07}; and 6) U.S. Serial No. t. 817,441 inc. Tabs 1-28 {Treannie Exh. 6, 11-7-07};					
	52	November 9, 2007 (Draft Transcript) Vincent, in Civil Action No. 06-259	of Matthew (MPT);	Perry	
	53	November 13, 2007 Transcript of Vid David L. Berstein, Ph.D., pgs. 1-32 Action No. 06-259 (MPT) including dwhich are attached with this Supple Disclosure Statement, namely: 1) Wye Deposition Pursuant to Fed. R. Civ. Harvard, MIT, And Whitehead {Berste November 5, 2007 correspondence from {Berstein Exh. 2, 11-13-07}; 3) Man Procedure {Berstein Exh. 3, 11-13-0 June 17, 1997 correspondence from I Exh. 5, 11-13-07}; 6) September 15, from Lisa Warren {Berstein Exh. 6, 8) February 17, 1998 correspondence {Berstein Exh. 8, 11-13-07}; 9) Not {Berstine Exh. 9, 11-13-07}; 10) A memorandum from Patricia Granahan { 07}; 11) May 15, 2000 correspondence {Berstein Exh. 11, 11-13-07}; 12) R 22, 1994 correspondence from Patric Exh. 13, 11-13-07}; 14) Redacted; 1 Redacted;	deposition Exemental Informeth's First N P. 30(b)(6) in Exh. 1, 1 m Nathan Lownual of Paten 17; 4) Redaisa Warren { 1997 corres 11-13-07}; 7 from Patric ice of Allow august 30, 19 Berstein Exh Redacted; 13) ia Granahan	, in Civil hibits 1-16 mation otice of To Ariad, 1-13-07;; 2) enstein t Examining cted; 5) Berstein pondence) Redacted; ia Granahan ance 94 . 10, 11-13- y Berger December {Berstein	
	54	November 29, 2007 Transcript of Dep Volume I, pgs. 2-150 & A.1-A.16 in (MPT);	osition of L Civil Action	aurie Allen, No. 06-259	
	55	November 30, 2007 Transcript of Dep Volume II, pgs. 151-271 & A.1-A.13 259 (MPT);	oosition of L in Civil Act	aurie Allen, ion No. 06-	

DATE CONSIDERED

EXAMINER SIGNATURE

10/037,341 Form PTO-1449 Substitute U.S. Department of Commerce **Application Number Patent and Trademark Office** Filing Date January 4, 2002 David Baltimore First Named Inventor et al. INFORMATION DISCLOSURE STATEMENT 1636 Art Unit (Use several sheets if necessary) D. Guzo Examiner Name 75723-ZA/JPW/GJG Attorney Docket No. NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city Initials No.1 and/or country where published. December 14, 2007 Transcript of Videotaped Deposition of 56 Harvey J. Berger, M.D., pgs. 1-146 & A.1-A.17 in Civil Action No. 06-259 (MPT);December 12, 2007 Transcript of Videotaped Deposition of 57 Lita Nelsen, pgs. 2-222 & A.1-A.23 in Civil Action No. 06-259 (MPT); December 18, 2007 Transcript of Deposition of Isabelle 58 Clauss, Volume I, pgs. 1-100 & A.1-A.10 in Civil Action No. 06-259 (MPT); February 22, 2008 Expert Report of David M. Livingston, M.D., in Civil Action No. 06-259 (MPT); February 22, 2008 Rebuttal Report of Jeffrey V. Ravetch, M.D., Ph.D., in Civil Action No. 06-259 (MPT); February 22, 2008 Rebuttal Expert Report of Randolph Wall, 61 Ph.D., in Civil Action No. 06-259 (MPT); March 7, 2008 Reply Expert Report of Warner Craig Greene, 62 M.D., Ph.D., in Civil Action No. 06-259 (MPT); December 11, 2007 Amgen Entities' first Amended Reply to 63 Ariad, Harvard, MIT, And Whitehead's Amended Counterclaims, in Civil Action No. 06-259 (MPT); January 22, 2008 Telephone Conference before Mary Pat 64 Thynge, U.S. Magistrate Judge, in Civil Action No. 06-259 (MPT); February 8, 2008 Defendants-Counterclaim-Plaintiffs Ariad's And The Institutions' Memorandum of Law In Support of Their

EXAMINER
SIGNATURE DATE CONSIDERED

(MPT);

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Motion To Amend Counterclaims, in Civil Action No. 06-259

Form P7	O-1	449 Substitute	U.S. Department of Commercial	e Application Number	10/037,341	
. 01111 1		···	Patent and Trademark Office		January 4, 20	102
			Tatent and Trademark Office			
INEODN	лат	ION DISCLOSI	DE CTATEMENT	First Named Inventor	et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Art Unit	1636	
(USE SEV	CIAL	succes ii necessar	Examiner Name	D. Guzo		
				Attorney Docket No.	<u> </u>	/GJC
					· · · · · · · · · · · · · · · · · · ·	
		,	NON PATENT LITERATURE D	OCUMENTS		
Examiner Initials	Cite No. ¹		author (in CAPITAL LETTERS), title on nal, serial, symposium, catalog, etc.) dato and/or country where	e, page(s), volume-issue nu		T ²
	66	of Defendant	2008 Declaration of Dass-Counterclaim-Plaint: ' Motion to Amend Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Counter-Coun	iffs Ariad's A	nd The	
		And The Inst Reply Memora	8 Defendants-Counterchitutions; Reply Memorandum in Support of The s, Civil Action No. 0	andum In Suppo eir Motion to	rt of Their	
	68	February 22, M.D., in Civ	2008 Expert Report of il Action No. 06-259	f James Mark J (MPT);	ackson,	
	69	the litigati Pharmaceutic	2008 Condensed Transoon captioned Amgen, Inals, Inc. et al., U.S Delaware, CA No. 06-2	nc. Et al. v. . District Cou	Ariad	
	70	in the litig <i>Pharmaceutic</i>	8 Reply Expert Report ation captioned Amgen als, Inc., et al., U.S Delaware, CA No. 06-25	, <i>Inc. et al.</i> S. District Co	v. Ariad	
	71	the litigati Pharmaceutic	2008 Condensed Transo on captioned Amgen, In als, Inc., et al., U.S Delaware, CA No. 06-25	nc. et al. v. 3. District Co	Ariad	
	72	Ph.D. in the <i>Ariad Pharma</i>	8 Reply Expert Report litigation captioned ceuticals, Inc., et a rict of Delaware, CA	Amgen, Inc. e l., U.S. Distr	<i>t al. v.</i> ict Court	
	73	Company's Mo Civ. P. 60(b Pharmaceutic	2007 Memorandum In Suption For Relief From () And for Additional Pals, Inc. v. Eli Lilly e District of Massach	Judgment Under Discovery, Ari y & Co, U.S. D	Fed. R. ad istrict	

DATE CONSIDERED

EXAMINER SIGNATURE

torm P	r O-1	449 Substitute	U.S. Department of Commerce	Application Number	10/037,341			
			Patent and Trademark Office	Filing Date	January 4, 20	002		
				Etuat Named Inventor	David Baltimo	ore		
VFORM	ИАТ	ION DISCLOSU	JRE STATEMENT	First Named Inventor	et al.			
Use several sheets if necessary)			Art Unit	1636				
			Examiner Name	D. Guzo				
				Attorney Docket No.	75723-ZA/JPW,	/GJ		
Examiner	Cin		NON PATENT LITERATURE DOC					
xaminer Initials	Cite No.1							
		November 15,	2007 Plaintiffs' Oppos	ition To Lil	lv's Renewed			
		Motion For J	he					
			A New Trial, Ariad Pha					
		Eli Lilly &	Co, U.S. District Court	for the Dist	trict of			
			es, in Civil Action No.					
		Do comb = = -	2007 0	* ' 1 7				
December 5, 2007 Opposition To Eli Lilly And Company's					mpany's			
		Motion For Relief From Judgment Under Fed. R. Civ. P. 60(b) (Redacted version of document filed under seal), including Exhibits 1-7, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts,						
	75							
		in Civil Act	ion No. 02-11280 RWZ;	CIICC OI Mas.	Jachusetts,			
		December 13,	2007 Reply In Support	of Defendant	's Renewed			
		Motion For J	Judgment As a Matter of	Law Or, In the	he			
	/6	Alternative,	A New Trial, Ariad Pha	rmaceuticals	, Inc. v.			
	Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280 RWZ;							
		Massachusett	.s, in Civil Action No.	02-11280 RWZ	; 			
		December 26,	2007 Sur-Reply In Supp	ort of Plain	tiff's			
1		Opposition T	Co Defendant's Renewed M	otion For Jud	dgment As a			
	77	Matter Of Law Or, In The Alternative, A New Trial, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action						
		No. 02-11280	RWZ;					
		February 8,	2008 Notice Of Suppleme	ntal Authori	tv.			
	70	including at	tachment, Ariad Pharmac	euticals, Inc	c. v. Eli			
		including attachment, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of						
		Massachusett	s, in Civil Action No.	02-11280 RWZ	;			
		March 10 00	100 Notice 15 7 7 7					
		march 10, 20	008 Notice of Appeal, Ar	lad Pharmace	iticals,			
1	79	Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280						
		RWZ;	massachusetts, III CIVII	ACCION NO. (JZ=1128U			
						_		
		March 18, 20	008 Notice of Docketing,	Ariad Pharma	aceuticals,			
	80	Inc. v. Eli	Lilly & Co, U.S. Distri	ct Court for	the			
-		District of	Massachusetts, in Civil	Action No. (02-11280 RWZ			
CAMINER			I I					

						Page 14 OI	_ 15	
Form P	ΓΟ-1	449 Substitute	U.S. Departm	nent of Commerce	Application Number	10/037,341		
Patent and Trademark Offic					Filing Date	January 4, 2002		
					First Named Inventor	David Baltimo	ore	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			ENT	rirst Named Inventor	et al.			
				Art Unit	1636			
,					Examiner Name	D. Guzo		
					Attorney Docket No.	75723-ZA/JPW,	/GJG	
			NON PATENT	LITERATURE DOC	UMENTS			
Examiner Initials*	Cite No. ¹	i men appropriately title of the item						
		Index of Civil Docket For Case No.: 1:02-cv-11280-RWZ starting from July 6, 2007, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts;						
	82	Brief on Cla	im Constru	nts-Countercl ction, U.S. D CA No. 06-259	istrict Cour	fs' Opening t for the		
		Their Motion U.S. Patent	For Summa No. 6,410, Delaware,	en Entities' ry Judgment o 516, U.S. Dis in Civil Acti er Seal;	f Noninfring trict Court	ement of for the		
	l	April 25, 2008 The Amgen Entities' Brief In Support of Their Motion to Preclude Ariad's Proffered Experts on Willfulness and Inequitable Conduct From Opining on Intent, State of Mind, and Other Matters, U.S. District Court for the District of Delaware, in Civil Action No. 06-259 (MPT) Public Version Confidential Material Omitted;						
	Q 5	Their Dauber Unreliable C Damages, U.S	t Motion T pinions of District ion No. 06	en Entities' o Preclude Ce Dr. Ryan Sul Court for th -259 (MPT) Pu Omitted;	rtain Unsuppelivan Relati: e District o	orted and ng to f Delaware,		
	86	Daubert Moti Dr. Jeffrey Inherent Ant	on To Prec V. Ravetch icipation,	en Entities' lude Certain Relating to U.S. Distric Action No. 06	Proffered Op Written Desc t Court for	inions of ription and		
	87	Counterclaim Lack of Subj	-Plaintiff ect Matter	dum In Suppor s' Motion for Jurisdiction laware, CA No	Partial Distr.	missal For		

EXAMINER SIGNATURE

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

-			ent of Commerce	10/037,341			
			Patent and Tr	ademark Office	Filing Date	January 4, 20	
					First Named Inventor	David Baltimo	ore
INFOR	MAT	TON DISCLOSU	J <mark>RE STATEM</mark> I	ENT		et al.	
(Use several sheets if necessary)					Art Unit	1636	
					Examiner Name	D. Guzo	
					Attorney Docket No.	75723-ZA/JPW,	/GJG
			NON PATENT	LITERATURE DOC	UMENTS		
Examiner Initials*							
	88	April 25, 20 the District	008 Covenant of Delawa	t Not To Sue, re, CA No. 06	U.S. Distri -259-MPT; an	ct Court for d	
	89	the litigati Pharmaceutio	ion captions cals, Inc.,	ot of Claim C ed <i>Amgen, Inc</i> et al., U.S. CA No. 06-259	. et al. v. District Co	Ariad	
							·
	!						-
EXAMINEF SIGNATUR				DATE CONSIDERED			

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.